Skip to Content

Franklin Biotechnology Discovery A FBDIX

Medalist Rating as of | See Franklin Templeton Investment Hub
  • NAV / 1-Day Return 147.57  /  +2.57 %
  • Total Assets 993.7 Mil
  • Adj. Expense Ratio
    1.070%
  • Expense Ratio 1.070%
  • Distribution Fee Level Low
  • Share Class Type Front Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield
  • Turnover 24%

USD | NAV as of Mar 01, 2024 | 1-Day Return as of Mar 01, 2024, 11:12 PM GMT+0

Morningstar’s Analysis FBDIX

Will FBDIX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Experienced team but not yet a standout.

Director Katie Rushkewicz Reichart

Katie Rushkewicz Reichart

Director

Summary

Franklin Biotechnology Discovery has an experienced team at the helm, but it needs to distinguish itself.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBDIX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 43.8
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Amgen Inc

8.52 76.4 Mil
Healthcare

Regeneron Pharmaceuticals Inc

6.81 61.1 Mil
Healthcare

Vertex Pharmaceuticals Inc

5.95 53.3 Mil
Healthcare

Ascendis Pharma A/S ADR

3.78 33.9 Mil
Healthcare

Gilead Sciences Inc

3.61 32.4 Mil
Healthcare

Biogen Inc

3.56 31.9 Mil
Healthcare

Franklin IFT Money Market

3.47 31.2 Mil
Cash and Equivalents

Intra-Cellular Therapies Inc

3.25 29.1 Mil
Healthcare

AstraZeneca PLC ADR

2.95 26.4 Mil
Healthcare

Jazz Pharmaceuticals PLC

2.70 24.2 Mil
Healthcare